Custom 4-plex DiLeu isobaric labels enable relative quantification of urinary proteins in men with lower urinary tract symptoms (LUTS)

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Greer, Tyler ^a   Hao, Ling ^a   Nechyporenko, Anatoliy ^a   Lee, Sanghee ^a   Vezina, Chad M ^b   Ricke, Will A ^a   Marker, Paul C ^a   Bjorling, Dale E ^b   Bushman, Wade ^a   Li, Lingjun ^a   Koomen, John Matthew ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; LEUCINE;

ALKYLATION; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CUSTOM 4 PLEX DILEU ISOBARIC LABEL; GENE ONTOLOGY; HUMAN; INFLAMMATION; LIQUID CHROMATOGRAPHY; LOWER URINARY TRACT SYMPTOM; MALE; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEOMICS; ADULT; AGED; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; MIDDLE AGED; PROCEDURES; PROTEINURIA; URINALYSIS; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; LEUCINE; LOWER URINARY TRACT SYMPTOMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEINURIA; URINALYSIS;

EID: 84943194233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135415     Document Type: Article

References (117)

1. Kalantari S, Nafar M, Rutishauser D., Samavat S, Rezaei-Tavirani M, Yang H, et al Predictive urinary biomarkers for steroid-resistant and steroid-sensitive focal segmental glomerulosclerosis using high resolution mass spectrometry and multivariate statistical analysis. BMC Nephrol. 2014; 15:141. doi: 10.1186/1471-2369-15-141 PMID: 25182141
2. Kalantari S, Rutishauser D, Samavat S., Nafar M, Mahmudieh L, Rezaei-Tavirani M, et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography. PLoSOne. 2013; 8. doi:10.1371/journal.pone.0080830
3. Menezesde Oliveira B, Matsumura CY, Fontes-Oliveira CC, Gawlik KI, Acosta H, Wernhoff P, et al. Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation and increased expression of extracellular matrix proteins in laminin α 2 chain-deficient muscle. Mol Cell Proteomics. 2014; doi: 10.1074/mcp.M113.032276
4. Betancourt A, Mobley JA, Wang J, Jenkins S, Chen D, Kojima K, et al. Alterations in the rat serum pro-teome induced by prepubertal exposure to bisphenol A and genistein. J Proteome Res. 2014; 13: 1502-1514. doi: 10.1021/pr401027q PMID: 24552547
5. Merl J, Ueffing M, Hauck SM, von Toerne C. Direct comparison of MS-based label-free and SILAC quantitative proteome profiling strategies in primary retinal Müller cells. Proteomics. 2012; 12:1902-11. doi: 10.1002/pmic.201100549 PMID: 22623344
6. Southey B, Lee J, Zamdborg L. Comparing Label-Free Quantitative Peptidomics Approaches to Characterize Diurnal Variation of Peptides in the Rat Suprachiasmatic Nucleus. Anal Chem. 2013; 86: 443-52. doi: 10.1021/ac4023378 PMID: 24313826
7. Titulaer MK, de Costa D, Stingl C, Dekker L.J., Sillevis Smitt PA, Luider TM. Label-free peptide profiling of Orbitrapfull mass spectra. BMC Res Notes. 2011; 4: 21. doi: 10.1186/1756-0500-4-21 PMID: 21272362
8. Zhang S, Cao X, He Y., Hartson S, Jiang H. Semi-quantitative analysis of changes in the plasma pepti-dome of Manduca sexta larvae and their correlation with the transcriptome variations upon immune challenge. Insect Biochem Mol Biol. 2014; 47: 46-54. doi: 10.1016/j.ibmb.2014.02.002 PMID: 24565606
9. Cunningham R, Jany P, Messing A., Li L. Protein changes in immunodepleted cerebrospinal fluid from a transgenic mouse model of Alexander disease detected using mass spectrometry. J Proteome Res. 2013; 12: 719-28. doi: 10.1021/pr300785h PMID: 23272901
10. Ong S-E. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics. Mol Cell Proteomics. 2002; 1: 376-386. doi: 10.1074/mcp. M200025-MCP200 PMID: 12118079
11. Ji C, Guo N, Li L. Differential dimethyl labeling of N-termini of peptides after guanidination for proteome analysis. J Proteome Res. 2005; 4: 2099-2108. doi: 10.1021/pr050215d PMID: 16335955
12. Gygi SP, Rist B, Gerber S.A., Turecek F., Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999; 17: 994-999. doi: 10.1038/13690 PMID: 10504701
13. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B, et al. 8-Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics. 2007; 7: 3651-3660. doi: 10.1002/pmic.200700316 PMID: 17880003
14. Hwang CY, Kim K, Choi J.Y., Bahn YJ, Lee S-M, Kim YK, et al Quantitative proteome analysis of age-related changes in mouse gastrocnemius muscle using mTRAQ. Proteomics. 2014; 14:121-32. doi: 10.1002/pmic.201200497 PMID: 24243720
15. Sinclair J, Timms JF Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. Methods. 2011; 54: 361-369. doi: 10.1016/j.ymeth.2011.03.004 PMID: 21397697
16. Dephoure N, Gygi SP Hyperplexing: A Method for Higher-Order Multiplexed Quantitative Proteomics Provides a Map of the Dynamic Response to Rapamycin in Yeast. Sci Signal. 2012; 5. doi:10.1126/scisignal.2002548
17. Evans AR, Robinson RAS. Global combined precursor isotopic labeling and isobaric tagging (cPI-LOT) approach with selective MS3 acquisition. Proteomics. 2013; 13: 3267-3272. doi: 10.1002/pmic. 201300198 PMID: 24124127
18. DeSouza L, Taylor A, Li W. Multiple reaction monitoring of mTRAQ-labeled peptides enables absolute quantification of endogenous levels of a potential cancer marker in cancerous and normal. J Proteome Res. 2008; 7: 3525-3534. Available: http://pubs.acs.org/doi/abs/10.1021/pr800312m doi: 10.1021/pr800312m PMID: 18630974
19. Boersema PJ, Aye TT, Van Veen TAB, Heck AJR, Mohammed S. Triplex protein quantification based on stable isotope labeling by peptide dimethylation applied to cell and tissue lysates. Proteomics. 2008; 8: 4624-4632. doi: 10.1002/pmic.200800297 PMID: 18850632
20. Zhang R, Sioma CS, Wang S, Regnier FE Fractionation of isotopically labeled peptides in quantitative proteomics. Anal Chem. 2001; 73: 5142-5149. doi: 10.1021/ac010583a PMID: 11721911
21. Mertins P, Udeshi ND, Clauser K.R., Mani DR, Patel J, Ong S, et al. iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012; 11. doi:10.1074/mcp.M111.014423
22. Hebert AS, Merrill AE, Bailey D.J., Still AJ, Westphall MS, Strieter ER, et al. Neutron-encoded mass signatures for multiplexed proteome quantification. Nat Methods. 2013; 10: 332-4. doi: 10.1038/nmeth.2378 PMID: 23435260
23. Hebert AS, Merrill AE, Stefely J.A., Bailey DJ, Wenger CD, Westphall MS, et al Amine-reactive neutron-encoded labels for highly plexed proteomic quantitation. Mol Cell Proteomics. 2013; 12: 3360-9. doi: 10.1074/mcp.M113.032011 PMID: 23882030
24. Richards AL, Vincent CE, Guthals A, Rose C.M., Westphall MS, Bandeira N, et al. Neutron-encoded signatures enable product ion annotation from tandem mass spectra. Mol Cell Proteomics. 2013; 12: 3812-23. doi: 10.1074/mcp.M113.028951 PMID: 24043425
25. Ulbrich A, Merrill AE, Hebert A.S., Westphall MS, Keller MP, Attie AD, et al Neutron-encoded protein quantification by peptide carbamylation. J Am Soc Mass Spectrom. 2014; 25: 6-9. doi: 10.1007/s13361-013-0765-z PMID: 24178922
26. Zhou L, Wei R, Zhao P., Koh SK, Beuerman RW, Ding C. Proteomic analysis revealed the altered tear protein profile in a rabbit model of Sjögren's syndrome-associated dry eye. Proteomics. 2013; 13: 2469-81. doi: 10.1002/pmic.201200230 PMID: 23733261
27. Jeanson L, Guerrera IC, Papon J-F, Chhuon C, Zadigue P., Prulière-Escabasse V, et al. Proteomic Analysis of Nasal Epithelial Cells from Cystic Fibrosis Patients. PLoS One. 2014; 9. doi:10.1371/journal.pone.0108671
28. Dean RA, Overall CM Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics. 2007; 6: 611-23. doi: 10.1074/mcp.M600341-MCP200 PMID: 17200105
29. Thompson A, Schäfer J, Kuhn K., Kienle S, Schwarz J, Schmidt G, et al. Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem. 2003; 75:1895-1904. doi: 10.1021/ac0262560 PMID: 12713048
30. DeSouza L, Diehl G, Rodrigues MJ, Guo J, Romaschin AD, Colgan TJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2005; 4: 377-386. doi: 10.1021/pr049821j PMID: 15822913
31. Xiang F, Ye H, Chen R., Fu Q, Li L. N, N-dimethyl leucines as novel isobaric tandem mass tags for quantitative proteomics and peptidomics. Anal Chem. 2010; 82: 2817-2825. doi: 10.1021/ac902778d PMID: 20218596
32. Hui L, Xiang F, Zhang Y., Li L. Mass spectrometric elucidation of the neuropeptidome of a crustacean neuroendocrine organ. Peptides. 2012; 36: 230-239. doi: 10.1016/j.peptides.2012.05.007 PMID: 22627023
33. Sturm RM, Lietz CB, Li L. Improved isobaric tandem mass tag quantification by ion mobility mass spectrometry. Rapid Commun Mass Spectrom. 2014; 28:1051-60. doi: 10.1002/rcm.6875 PMID: 24677527
34. Engström G., Henningsohn L, Steineck G., Leppert J. Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int. 2005; 95: 810-5. doi: 10.1111/j.1464-410X.2005.05406.x PMID: 15794788
35. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005; 173:1309-13. doi: 10.1097/01.ju.0000152318.79184.6f PMID: 15758787
36. Cannon GW, Mullins C, Lucia M.S., Hayward SW, Lin V, Liu BCS, et al. A Preliminary Study of JM-27: A Serum Marker That Can Specifically Identify Men With Symptomatic Benign Prostatic Hyperplasia. J Urol. 2007; 177: 610-614. doi: 10.1016/j.juro.2006.09.023 PMID: 17222644
37. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005; 7 Suppl 9: S3-S14. PMID: 16985902
38. Abrams P, Cardozo L, Fall M., Griffiths D, Rosier P, Ulmsten U., et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61: 37-49. doi: 10.1016/S0090-4295(02)02243-4 PMID: 12559262
39. Chapple CR, Roehrborn CG A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49: 651-8. doi: 10.1016/j.eururo.2006.02.018 PMID: 16530611
40. Bierhoff E, Vogel J, Benz M., Giefer T, Wernert N, Pfeifer U. Stromal nodules in benign prostatic hyperplasia. Eur Urol. 1996; 29:345-354. PMID: 8740022
41. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001; 54: 935-944. doi: 10.1016/S0895-4356(01)00351-1 PMID: 11520654
42. Hammarsten J, Högstedt B. Hyperinsulinaemiaas a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001; 39:151-158. doi: 10.1159/000052430 PMID: 11223674
43. Verhamme KMC, Dieleman JP, Bleumink GS, Lei J Van Der. Incidence and Prevalence of Lower UrinaryT ract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Careo-The Triumph Project. Eur Urol. 2002; 42: 323-328. PMID: 12361895
44. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am. 1990; 17: 477-486. PMID: 1695776
45. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978; 15: 340-345. PMID: 75197
46. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009; 36: 403-415. doi: 10.1016/j.ucl.2009.07.003 PMID: 19942041
47. Michel M, de la Rosette J. Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. Eur Urol Suppl. 2009; 8: 496-503. doi:10.1016/j.eursup.2009.02.001
48. Oelke M, Bachmann A, Descazeaud A., Emberton M, Gravas S, Michel M.C., et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013; 64:118-140. doi: 10.1016/j.eururo.2013.03.004 PMID: 23541338
49. Nickel J, Downey J, Young I., Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999; 84: 976-981. Available: http://onlinelibrary.wiley.com/doi/10.1046/j.1464-410x.1999.00352.x/full PMID: 10571623
50. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, et al. Evaluation of Prostatitis in Autopsied Prostates-Is Chronic Inflammation More Associated With Benign Prostatic Hyperplasia or Cancer? J Urol. 2008; 179:1736-1740. doi: 10.1016/j.juro.2008.01.034 PMID: 18343414
51. Kohnen PW, Drach GW Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979; 121: 755-760. PMID: 88527
52. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al. Phenotypiccharacterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992; 66: 96-107. PMID: 1370561
53. Steiner G, Gessl A, Kramer G, Schöllhammer A, Förster O, Marberger M. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol. 1994; 151: 480-484. PMID: 7506795
54. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007; 51:1202-16. doi: 10.1016/j.eururo.2006.12.011 PMID: 17182170
55. Wong L, Hutson PR, Bushman W. Prostatic inflammation induces fibrosis in a mouse model of chronic bacterial infection. PLoSOne. 2014; 9. doi:10.1371/journal.pone.0100770
56. Lee S, Yang G, Mulligan W., Gipp J, Bushman W. Ventral prostate fibrosis in the Akita mouse is associated with macrophage and fibrocyte infiltration. J Diabetes Res. Hindawi Publishing Corporation; 2014; 939053. doi: 10.1155/2014/939053 PMID: 25019092
57. Wong L, Hutson PR, Bushman W. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate. 2014; doi: 10.1002/pros.22886
58. Bercovich E, Barabino G, Pirozzi-Farina F, Deriu M. A multivariate analysis of lower urinary tract ageing and urinary symptoms: the role of fibrosis. Arch Ital Urol Androl. 1999; 71: 287-292. PMID: 10673792
59. Ma J, Gharaee-Kermani M, Kunju L., Hollingsworth JM, Adler J, Arruda EM, et al Prostatic Fibrosis is Associated with Lower Urinary Tract Symptoms. J Urol. 2012; 188:1375-1381. doi: 10.1016/j.juro.2012.06.007 PMID: 22906651
60. Bauman TM, Nicholson TM, Abler LL, Eliceiri KW, Huang W, Vezina CM, et al. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS One. 2014; 9: e109102. doi: 10.1371/journal.pone.0109102 PMID: 25275645
61. Cantiello F, Cicione A, Salonia A, Autorino R, Tucci L, Madeo I, et al. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology. Elsevier Inc.; 2013; 81:1018-23. doi: 10.1016/j.urology.2013.01.053 PMID: 23608423
62. Bélanger A., Candas B, Dupont A., Cusan L, Diamond P, Gomez J.L., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40-to 80-year-old men. J Clin Endocrinol Metab. 1994; 79:1086-1090. doi: 10.1210/jc.79.4.1086 PMID: 7962278
63. Walsh P, Wilson J. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest. 1976; 57:10-14. doi:10.1172/JCI108353.The
64. Aumuller G, Funke PJ, Hahn A, Hoffbauer G, Tunn U, Neumann F. Phenotypic modulation of the canine prostate after long-term treatment with androgens and estrogens. Prostate. 1982; 3: 361-373. doi: 10.1002/pros.2990030406 PMID: 6181496
65. Winter ML, Bosland MC, Wade D.R., Falvo RE, Nagamani M, Liehr JG. Induction of benign prostatic hyperplasia in intact dogs by near-physiological levels of 5alpha-dihydrotestosteroneand 17 beta-estradiol. Prostate. 1995; 26: 325-333. PMID: 7540298
66. Mahapokai W, Xue Y, Van Garderen E, Van Sluijs FJ, Mol JA, Schalken JA. Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. Prostate. 2000; 44: 40-48. doi: 10. 1002/1097-0045(20000615)44:1<40::AID-PROS6>3.0.CO;2-J PMID: 10861756
67. Constantinou CE, Omata S. Analysis of the relative biomechanical effects of α1 and α2 antagonists in modifying the compliance of the prostate and micturition parameters of the hormonally manipulated male rat. Neurourol Urodyn. 1996; 15: 85-101. doi: 10.1002/(SICI)1520-6777(1996)15:1<85::AID-NAU9>3.0.CO;2-B PMID: 8696360
68. Zhou Y, Xiao X-Q, Chen L-F, Yang R, Shi J-D, Du X-L, et al. Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. Asian J Androl. 2009; 11: 451-9. doi: 10.1038/aja.2009.28 PMID: 19483715
69. Kitsberg DI, Leder P. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene. 1996; 13: 2507-2515. PMID: 9000125
70. Nicholson TM, Ricke EA, Marker P.C., Miano JM, Mayer RD, Timms BG, et al Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice. Endocrinology. 2012; 153: 5556-65. doi: 10.1210/en.2012-1522 PMID: 22948219
71. Käll L., Canterbury JD, Weston J, Noble W.S., MacCoss MJ. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods. 2007; 4: 923-925. doi: 10.1038/nmeth1113 PMID: 17952086
72. Shadforth IP, Dunkley TPJ, Lilley KS, Bessant C. i-Tracker: for quantitative proteomics using iTRAQ. BMC Genomics. 2005; 6: 145. doi: 10.1186/1471-2164-6-145 PMID: 16242023
73. Huang DW, Sherman BT, Lempicki RA Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57. doi: 10.1038/nprot.2008.211 PMID: 19131956
74. Lavallée-Adam M., Rauniyar N, McClatchy D.B., Yates JR. PSEA-Quant: A protein set enrichment analysis on label-free and label-based protein quantification data. J Proteome Res. 2014; doi: 10.1021/pr500473n
75. Greer T, Lietz CB, Xiang F, Li L. Novel isotopic N, N-Dimethyl Leucine (iDiLeu) Reagents Enable Absolute Quantification of Peptides and Proteins Using a Standard Curve Approach. J Am Soc Mass Spectrom. 2015; 26: 107-119. doi: 10.1007/s13361-014-1012-y PMID: 25377360
76. Frost DC, Greer T, Li L. High-Resolution Enabled 12-Plex DiLeu Isobaric Tags for Quantitative Proteomics. Anal Chem. 2015; 87: 1646-1654. doi: 10.1021/ac503276z PMID: 25405479
77. Eng JK, McCormack AL, Yates JR An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom. 1994; 5: 976-89. doi: 10.1016/1044-0305(94)80016-2 PMID: 24226387
78. Ow SY, Salim M, Noirel J., Evans C, Rehman I, Wright PC iTRAQ underestimation in simple and complex mixtures: "the good, the bad and the ugly". J Proteome Res. 2009; 8: 5347-5355. doi: 10.1021/pr900634c PMID: 19754192
79. Savitski MM, Sweetman G, Askenazi M., Marto JA, Lang M, Zinn N, et al Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on orbitrap-type mass spectrometers. Anal Chem. 2011; 83: 8959-8967. doi: 10.1021/ac201760x PMID: 22017476
80. Savitski MM, Mathieson T, Zinn N., Sweetman G, Doce C, Becher I, et al. Measuring and managing ratio compression for accurate iTRAQ/TMT quantification. J Proteome Res. 2013; 12: 3586-3598. doi: 10.1021/pr400098r PMID: 23768245
81. Wenger CD, Lee MV, Hebert AS, McAlister GC, Phanstiel DH, Westphall MS, et al. Gas-phase purification enables accurate, multiplexed proteome quantification with isobaric tagging. Nat Methods. 2011; 8: 933-935. doi: 10.1038/nmeth.1716 PMID: 21963608
82. Ting L, Rad R, Gygi S.P., Haas W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat Methods. 2011; 8: 937-940. doi: 10.1038/nmeth.1714 PMID: 21963607
83. McAlister GC, Nusinow DP, Jedrychowski MP, Wühr M, Huttlin EL, Erickson BK, et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal Chem. 2014; 86: 7150-7158. doi: 10.1021/ac502040v PMID: 24927332
84. Stanke F, Becker T, Cuppens H, Kumar V, Cassiman J-J, Jansen S, et al. TheTNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet. 2006; 119: 331-43. doi: 10.1007/s00439-006-0140-2 PMID: 16463024
85. Azad AK, Rauh R, Vermeulen F., Jaspers M, Korbmacher J, Boissier B., et al. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum Mutat. 2009; 30: 1093-1103. doi: 10.1002/humu.21011 PMID: 19462466
86. Ranganathan K, Kavitha R, Sawant S.S., Vaidya MM. Cytokeratin expression in oral submucous fibrosis - an immunohistochemical study. J Oral Pathol Med. 2006; 35: 25-32. doi: 10.1111/j.1600-0714.2005.00366.x PMID: 16393250
87. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med. 2005; 37: 2-12. doi: 10.1080/07853890410018925 PMID: 15902842
88. Darrah R, McKone E, O'Connor C, Rodgers C, Genatossio A., McNamara S, et al. EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics. 2010; 41: 71-7. doi: 10.1152/physiolgenomics.00185.2009 PMID: 20028935
89. Boeker KHW, Haberkorn CI, Michels D, Flemming P., Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. 2002; 316: 71-81. doi: 10.1016/S0009-8981(01)00730-6 PMID: 11750276
90. Dihazi H, Dihazi GH, Mueller C, Lahrichi L., Asif AR, Bibi A, et al. Proteomics characterization of cell model with renal fibrosis phenotype: osmotic stress as fibrosis triggering factor. J Proteomics. Elsevier B.V.; 2011; 74: 304-18. doi: 10.1016/j.jprot.2010.11.007 PMID: 21118732
91. Eltoweissy M, Müller G a, Bibi A, Nguye P Van, Dihazi GH, Müller Ca, et al. Proteomics analysis identifies PARK7asan important player for renal cell resistance and survival under oxidative stress. Mol Biosyst. 2011; 7:1277-88. doi: 10.1039/c0mb00116c PMID: 21308111
92. De Lisle R., Petitt M, Huff J, Isom K, Agbasa. MUCLIN expression in the cystic fibrosis transmembrane conductance regulator knockout mouse. Gastroenterology. 1997; 113: 521-532. doi: 10.1053/gast.1997.v113.pm9247472 PMID: 9247472
93. Tzortzaki EG, Tischfield J a, Sahota A, Siafakas N.M., Gordon MK, Gerecke DR. Expression of FACIT collagens XII and XIV during bleomycin-induced pulmonary fibrosis in mice. Anat Rec A Discov Mol Cell Evol Biol. 2003; 275:1073-80. doi: 10.1002/ar.a.10120 PMID: 14613307
94. Casini A, Ceni E, Salzano R., Schuppan D, Milani S, Pellegrini G., et al. Regulation of undulin synthesis and gene expression in human fat-storing cells by acetaldehyde and transforming growth factor-beta 1: comparison with fibronectin. Biochem Biophys Res Commun. 1994; 199:1019-1026. doi:S0006-291X(84)71331-3 [pii] \ doi: 10.1006/bbrc.1994.1331 PMID: 8135774
95. Sulyok S, Wankell M, Alzheimer C, Werner S. Activin: an important regulator of wound repair, fibrosis, and neuroprotection. Mol Cell Endocrinol. 2004; 225:127-32. doi: 10.1016/j.mce.2004.07.011 PMID: 15451577
96. Raju R, Jian B, Hooks J.J., Nagineni CN. Transforming growth factor-β regulates the expression of anosmin (KAL-1) in human retinal pigment epithelial cells. Cytokine. 2013; 61: 724-727. doi: 10.1016/j.cyto.2012.12.019 PMID: 23357298
97. Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl). 2008; 86: 507-22. doi:10.1007/s00109-007-0301-3
98. Wills-Karp M., Rani R, Dienger K, Lewkowich I, Fox JG, Perkins C, et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med. 2012; 209: 607-22. doi: 10.1084/jem.20110079 PMID: 22329990
99. Jablonska E, Markart P, Zakrzewicz D., Preissner KT, Wygrecka M. Transforming growth factor-β1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts. J Biol Chem. 2010; 285:11638-51. doi: 10.1074/jbc.M109.045963 PMID: 20142324
100. Milner K-L, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KSL, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009; 49:1926-34. doi: 10.1002/hep.22896 PMID: 19475694
101. De Lisle R.C., Sewell R, Meldi L. Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine. Neurogastroenterol Motil. 2010; 22: 341-e87. doi: 10.1111/j.1365-2982.2009.01418.x PMID: 19814773
102. Kanno Y, Kuroki A, Okada K., Tomogane K, Ueshima S, Matsuo O., et al. Alpha2-antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis. J Thromb Haemost. 2007; 5: 2266-2273. doi: 10.1111/j.1538-7836.2007.02745.x PMID: 17958745
103. Muramatsu T. Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System. Curr Pharm Des. 2011; 17: 410-423. doi: 10.2174/138161211795164167 PMID: 21375488
104. Sousa MM, Norden a G, Jacobsen C, Willnow TE, Christensen EI, ThakkerR V, et al. Evidence for the role of megalin in renal uptake of transthyretin. J Biol Chem. 2000; 275: 38176-81. doi: 10.1074/jbc.M002886200 PMID: 10982792
105. Saban MR, Hellmich HL, Turner M, Nguyen N-B, Vadigepalli R, Dyer D.W., et al. The inflammatory and normal transcriptome of mouse bladder detrusor and mucosa. BMC Physiol. 2006; 6:1. doi: 10.1186/1472-6793-6-1 PMID: 16420690
106. Sanchez-Niño MD, Sanz AB, Sanchez-Lopez E, Ruiz-Ortega M, Benito-Martin A, Saleem M a, et al. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. Lab Invest. 2012; 92: 32-45. doi: 10.1038/labinvest.2011.138 PMID: 21931298
107. Cairo ER, Friedrich T, Swarts HGP, Knoers N V, Bindels RJM, Monnens La, et al Impaired routing of wild type FXYD2 after oligomerisation with FXYD2-G41R might explain the dominant nature of renal hypomagnesemia. Biochim Biophys Acta. 2008; 1778: 398-404. doi: 10.1016/j.bbamem.2007.10.009 PMID: 17980699
108. Omacini S, Mione R, Barichello M., Santucci Delli Ponti U, Bolgan A, Contemori GP, et al. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer? Eur Urol. 1992; 21 Suppl 1:108-110. PMID: 1385128
109. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol. 1999; 10: 2323-2331. PMID: 10541291
110. Stebbing J, Lit LC, Zhang H, Darrington R.S., Melaiu O., Rudraraju B, et al. The regulatory roles of phosphatases in cancer. Oncogene. Nature Publishing Group; 2014; 33: 939-53. doi: 10.1038/onc.2013. 80 PMID: 23503460
111. Kitamura H, Torigoe T, Hirohashi Y, Asanuma H., Inoue R, Nishida S, et al. Prognostic impact of the expression of ALDH1 and SOX2in urothelial cancer of the upper urinary tract. Mod Pathol. Nature Publishing Group; 2013; 26:117-24. doi: 10.1038/modpathol.2012.139 PMID: 22899292
112. Mirtti T, Alanen K, Kallajoki M., Rinne A, Söderström KO. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Prostate. 2003; 54: 290-298. doi: 10.1002/pros.10196 PMID: 12539227
113. Rosen R, Altwein J, Boyle P., Kirby RS, Lukacs B, Meuleman E, et al Lower Urinary Tract Symptoms and Male Sexual Dysfunction: The Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003; 44: 637-649. doi: 10.1016/j.eururo.2003.08.015 PMID: 14644114
114. Hellstrom WJG, Giuliano F, Rosen RC Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology. Elsevier Inc.; 2009; 74: 15-21. doi: 10.1016/j.urology.2008.06.048 PMID: 19428091
115. Prat AG, Cunningham CC, Jackson G.R., Borkan SC, Wang Y, Ausiello DA, et al Actin filament organization is required for proper cAMP-dependent activation of CFTR. Am J Physiol. 1999; 277: C1160-C1169. PMID: 10600767
116. Cantiello HF. Role of the actin cytoskeleton in the regulation of the cystic fibrosis transmembrane conductance regulator. Exp Physiol. 1996; 81: 505-514. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&listuids=8737083
117. Ivanov AI, Parkos CA, Nusrat A. Cytoskeletal regulation of epithelial barrier function during inflammation. Am J Pathol. 2010; 177: 512-24. doi: 10.2353/ajpath.2010.100168 PMID: 20581053